Pluri Past Earnings Performance
Past criteria checks 0/6
Pluri has been growing earnings at an average annual rate of 7.8%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 56.1% per year.
Key information
7.8%
Earnings growth rate
27.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 56.1% |
| Return on equity | n/a |
| Net Margin | -3,647.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Pluri gains as PROTO project receives €7.5M EU grant
Sep 06Pluristem Therapeutics renames as Pluri
Jul 25Pluristem Therapeutics (NASDAQ:PSTI) Has Debt But No Earnings; Should You Worry?
Dec 04
We Think Pluristem Therapeutics (NASDAQ:PSTI) Needs To Drive Business Growth Carefully
Aug 18What Is The Ownership Structure Like For Pluristem Therapeutics Inc. (NASDAQ:PSTI)?
Mar 15We're Hopeful That Pluristem Therapeutics (NASDAQ:PSTI) Will Use Its Cash Wisely
Feb 08
Pluristem Therapeutics launches $30M registered direct offering
Feb 02Have Insiders Been Buying Pluristem Therapeutics Inc. (NASDAQ:PSTI) Shares?
Jan 04Pluristem expands COVID-19 program in Mexico
Dec 29Pluristem - Moment Of Truth
Dec 08Market Sentiment Around Loss-Making Pluristem Therapeutics Inc. (NASDAQ:PSTI)
Nov 30Revenue & Expenses Breakdown
How Pluri makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1 | -22 | 10 | 12 |
| 30 Jun 24 | 0 | -21 | 10 | 12 |
| 31 Mar 24 | 0 | -22 | 10 | 13 |
| 31 Dec 23 | 0 | -24 | 11 | 14 |
| 30 Sep 23 | 0 | -27 | 11 | 14 |
| 30 Jun 23 | 0 | -28 | 12 | 16 |
| 31 Mar 23 | 0 | -31 | 12 | 18 |
| 31 Dec 22 | 0 | -33 | 14 | 20 |
| 30 Sep 22 | 0 | -36 | 15 | 22 |
| 30 Jun 22 | 0 | -41 | 17 | 24 |
| 31 Mar 22 | 0 | -47 | 21 | 27 |
| 31 Dec 21 | 0 | -51 | 23 | 28 |
| 30 Sep 21 | 0 | -53 | 24 | 29 |
| 30 Jun 21 | 0 | -50 | 22 | 29 |
| 31 Mar 21 | 0 | -43 | 18 | 27 |
| 31 Dec 20 | 0 | -37 | 13 | 25 |
| 30 Sep 20 | 0 | -31 | 10 | 21 |
| 30 Jun 20 | 0 | -29 | 9 | 21 |
| 31 Mar 20 | 0 | -29 | 8 | 21 |
| 31 Dec 19 | 0 | -31 | 8 | 23 |
| 30 Sep 19 | 0 | -34 | 9 | 25 |
| 30 Jun 19 | 0 | -35 | 9 | 26 |
| 31 Mar 19 | 0 | -37 | 11 | 26 |
| 31 Dec 18 | 0 | -28 | 11 | 24 |
| 30 Sep 18 | 0 | -28 | 12 | 24 |
| 30 Jun 18 | 0 | -26 | 11 | 23 |
| 31 Mar 18 | 0 | -24 | 11 | 20 |
| 31 Dec 17 | 0 | -30 | 11 | 20 |
| 30 Sep 17 | 0 | -29 | 9 | 20 |
| 30 Jun 17 | 0 | -28 | 8 | 20 |
| 31 Mar 17 | 0 | -27 | 8 | 20 |
| 31 Dec 16 | 0 | -26 | 7 | 19 |
| 30 Sep 16 | 3 | -24 | 8 | 19 |
| 30 Jun 16 | 3 | -23 | 8 | 19 |
| 31 Mar 16 | 3 | -22 | 7 | 18 |
| 31 Dec 15 | 3 | -22 | 7 | 19 |
| 30 Sep 15 | 0 | -25 | 7 | 18 |
| 30 Jun 15 | 0 | -25 | 7 | 18 |
| 31 Mar 15 | 0 | -26 | 8 | 19 |
| 31 Dec 14 | 0 | -28 | 9 | 19 |
| 30 Sep 14 | 0 | -28 | 9 | 19 |
| 30 Jun 14 | 0 | -27 | 10 | 19 |
| 31 Mar 14 | 0 | -28 | 9 | 20 |
| 31 Dec 13 | 0 | -24 | 7 | 18 |
Quality Earnings: PLUR is currently unprofitable.
Growing Profit Margin: PLUR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PLUR is unprofitable, but has reduced losses over the past 5 years at a rate of 7.8% per year.
Accelerating Growth: Unable to compare PLUR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PLUR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: PLUR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.